Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity - Archive ouverte HAL
Article Dans Une Revue Circulation Année : 2017

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity

Fabrice Barlesi
Stephane Ederhy

Résumé

Immune checkpoint inhibitors (ICIs) represent a major advance in the treatment of cancer. Although clinical trials reported a low incidence of immune-related cardiovascular adverse events, the number of published life-threatening cases of cardiotoxicity is increasing. In this descriptive observational analysis, we aimed to describe the clinical manifestations, management, and outcomes of patients who developed ICI-related cardiotoxicity.
Fichier principal
Vignette du fichier
Clinical Feature, Manag Escudier.pdf (85.44 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01729764 , version 1 (23-05-2018)

Identifiants

Citer

Marion Escudier, Jennifer Cautela, Nausicaa Malissen, Yann Ancedy, Morgane Orabona, et al.. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation, 2017, 136 (21), pp.2085-2087. ⟨10.1161/CIRCULATIONAHA.117.030571⟩. ⟨hal-01729764⟩
227 Consultations
307 Téléchargements

Altmetric

Partager

More